Investigating how ARID4B affects estrogen receptor signaling in breast cancer
Molecular Function and Mechanism of ARID4B in ERalpha Signaling and Breast Cancer
This study is looking at a protein called ARID4B to see how it affects the way estrogen signals in breast cancer, especially for patients whose tumors no longer respond to standard treatments, with the goal of finding new ways to help improve their care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-10886765 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a protein called ARID4B in the signaling pathways of estrogen receptors, which are crucial in many breast cancers. The study aims to uncover how ARID4B contributes to the development of resistance to standard endocrine therapies in patients with ERα+ breast cancer. By analyzing genomic data and conducting laboratory experiments, the researchers hope to identify new therapeutic targets that could improve treatment outcomes for patients with advanced breast cancer. This research is particularly relevant for those whose tumors have become resistant to current treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ERα+ breast cancer, particularly those with advanced or metastatic disease.
Not a fit: Patients with ERα- breast cancer or those who do not have advanced disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies for patients with advanced breast cancer who are resistant to existing therapies.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in breast cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
Washington, United States
- George Washington University — Washington, United States (Active)
Researchers
- Principal investigator: Wu, Ray-Chang — George Washington University
- Study coordinator: Wu, Ray-Chang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.